Frequent inactivation of PTEN in prostate cancer cell lines and xenografts.
about
PI3K/PTEN/AKT signaling regulates prostate tumor angiogenesisBeta2-microglobulin signaling blockade inhibited androgen receptor axis and caused apoptosis in human prostate cancer cellsModulation of prostate cancer genetic risk by omega-3 and omega-6 fatty acidsDiscovery of 4-Amino-1-(7 H -pyrrolo[2,3- d ]pyrimidin-4-yl)piperidine-4-carboxamides As Selective, Orally Active Inhibitors of Protein Kinase B (Akt)Ceramide dissociates 3'-phosphoinositide production from pleckstrin homology domain translocationLoss of PTEN permits CXCR4-mediated tumorigenesis through ERK1/2 in prostate cancer cellsKLF5 inhibits angiogenesis in PTEN-deficient prostate cancer by attenuating AKT activation and subsequent HIF1α accumulationRestoration of PTEN expression alters the sensitivity of prostate cancer cells to EGFR inhibitors.Early onset of neoplasia in the prostate and skin of mice with tissue-specific deletion of PtenInduction of FLIP expression by androgens protects prostate cancer cells from TRAIL-mediated apoptosisPiperlongumine inhibits NF-κB activity and attenuates aggressive growth characteristics of prostate cancer cellsHaploinsufficiency of the Pten tumor suppressor gene promotes prostate cancer progression.Decreased expression and androgen regulation of the tumor suppressor gene INPP4B in prostate cancer.MiR-205 is progressively down-regulated in lymph node metastasis but fails as a prognostic biomarker in high-risk prostate cancer.IFN induces miR-21 through a signal transducer and activator of transcription 3-dependent pathway as a suppressive negative feedback on IFN-induced apoptosis.TRAIL/Apo-2L: mechanisms and clinical applications in cancer.Klf5 deletion promotes Pten deletion-initiated luminal-type mouse prostate tumors through multiple oncogenic signaling pathwaysThe anti-proliferative effects of enterolactone in prostate cancer cells: evidence for the role of DNA licencing genes, mi-R106b cluster expression, and PTEN dosage.The ETS gene ETV4 is required for anchorage-independent growth and a cell proliferation gene expression program in PC3 prostate cells.Sortilin regulates progranulin action in castration-resistant prostate cancer cellsFour microRNAs promote prostate cell proliferation with regulation of PTEN and its downstream signals in vitroComparison of chromosomal and array-based comparative genomic hybridization for the detection of genomic imbalances in primary prostate carcinomas.Androgen-independent prostate cancer: potential role of androgen and ErbB receptor signal transduction crosstalkEffect of dietary polyunsaturated fatty acids on castration-resistant Pten-null prostate cancer.Tyrosine kinases expressed in vivo by human prostate cancer bone marrow metastases and loss of the type 1 insulin-like growth factor receptorAGE/RAGE/Akt pathway contributes to prostate cancer cell proliferation by promoting Rb phosphorylation and degradationEGF prevents the neuroendocrine differentiation of LNCaP cells induced by serum deprivation: the modulator role of PI3K/AktSignaling mechanisms coupled to CXCL12/CXCR4-mediated cellular proliferation are PTEN-dependent.Sorafenib decreases proliferation and induces apoptosis of prostate cancer cells by inhibition of the androgen receptor and Akt signaling pathwaysα(V)β(6) integrin expression is induced in the POET and Pten(pc-/-) mouse models of prostatic inflammation and prostatic adenocarcinoma.Suberoylanilide hydroxamic acid (SAHA; vorinostat) suppresses translation of cyclin D1 in mantle cell lymphoma cells.JNK and PTEN cooperatively control the development of invasive adenocarcinoma of the prostate.BMCC1, which is an interacting partner of BCL2, attenuates AKT activity, accompanied by apoptosis.Regulators of gene expression as biomarkers for prostate cancerβ4 Integrin signaling induces expansion of prostate tumor progenitorsDp44mT targets the AKT, TGF-β and ERK pathways via the metastasis suppressor NDRG1 in normal prostate epithelial cells and prostate cancer cells.Targeting prostate cancer based on signal transduction and cell cycle pathways.HDAC6 activity is not required for basal autophagic flux in metastatic prostate cancer cells.1Alpha,25-dihydroxyvitamin D3 reduces c-Myc expression, inhibiting proliferation and causing G1 accumulation in C4-2 prostate cancer cells.Advancing precision medicine for prostate cancer through genomics.
P2860
Q23914949-782813EC-6554-426E-8018-A662B3058B02Q24631263-6B17BC07-D711-4FD5-ADF0-B4CED3A84A4EQ24674656-50F2B056-D07F-4799-BBC2-FB88C71E6133Q27659777-D40B6865-B7FC-44F2-AD8F-96525EAC5667Q28348363-275A744B-6D5E-4BB4-BF33-167372AFFC5FQ28388722-AE5A1694-4F3C-4E2C-A2B2-D451B83524E2Q28393007-C10BDCC3-93AC-42CE-AC50-BCE1A8D0F9D9Q30438487-B94A4F6A-4780-4479-BE97-DBE153FCD5F5Q30524175-81100B18-6F0F-4807-91CD-DD6246EE6F22Q33363331-D8AA8E8E-0267-43B9-8520-63B0BFDBB03CQ33738321-05644497-FCDF-4013-B1CF-30511EC506B5Q33944717-3E1C6371-247D-47A2-AC7D-85C3633D28E7Q34158474-140D163F-7BF8-4C65-8C39-D4CF481CDFBFQ34381328-737A72D3-E9F2-4138-9DA5-3E06102133C2Q34461211-DDBA70C8-0BA7-4CC4-9B96-A4ECDCDC580FQ34482821-26A2984B-27BD-444A-B8E4-28A42CD18B3FQ34558936-5C15A621-7D1B-4927-8FFE-CE9CA84CF8C1Q34577999-66E90892-9EFE-4025-9360-42DB5E0FEF39Q34613397-CC25985A-68EF-4FCA-AB94-0CFB79379E1DQ34745270-41250E8D-BCAF-4DC4-8E3A-AB983C31569BQ35010133-7C80FC3B-18C8-4B4A-B53A-3946DB2A691EQ35039874-F67DF4DD-1EC1-46D7-A48D-A01E151A96DAQ35092971-297F1C24-C2E0-45CD-917C-14BEB608798BQ35730706-EC800204-B23A-4FA3-9F84-72C6D8D35126Q35788293-37E5D446-CA17-4CCC-8DB8-95A1D4E646DDQ35835242-6097626D-F3E4-47AB-A1FF-4A98BDBD8F1FQ35945055-2A92174C-CFB1-4886-9E5E-F9FA8355B7F7Q35962850-33AF3434-021E-4098-A8BE-AC1A74573351Q35963384-85A560A7-0346-4D2E-9680-887F89564D11Q35964178-95DB24EB-9A35-4310-9F5E-8E1EEAD139A9Q36007656-E774F7DA-98E9-4C77-AB90-5FCB08EC0985Q36132632-FDB4E807-4312-4838-A09D-EDA2D0E6E5C4Q36347152-57B8C8C4-7866-46F6-A0CF-E0D60A06CB92Q36439912-6C990366-D099-4F12-A778-87622633FC9BQ36580342-B3D6205D-105B-46AA-8122-4415E1687E59Q36594041-9D4991F5-9B18-4583-955B-D018FD102E55Q36995054-D5A81FB4-011D-44B9-A7F0-C9F977703476Q37107018-BDF76A0C-EF95-4D1D-8624-4CBA0CD60CCBQ37165972-AFD52407-407C-4A19-9619-B8D49B01CC7FQ37255151-57C3C6A0-100E-41CE-97E0-7ED45C3C6D15
P2860
Frequent inactivation of PTEN in prostate cancer cell lines and xenografts.
description
1998 nî lūn-bûn
@nan
1998年の論文
@ja
1998年学术文章
@wuu
1998年学术文章
@zh
1998年学术文章
@zh-cn
1998年学术文章
@zh-hans
1998年学术文章
@zh-my
1998年学术文章
@zh-sg
1998年學術文章
@yue
1998年學術文章
@zh-hant
name
Frequent inactivation of PTEN in prostate cancer cell lines and xenografts.
@en
Frequent inactivation of PTEN in prostate cancer cell lines and xenografts.
@nl
type
label
Frequent inactivation of PTEN in prostate cancer cell lines and xenografts.
@en
Frequent inactivation of PTEN in prostate cancer cell lines and xenografts.
@nl
prefLabel
Frequent inactivation of PTEN in prostate cancer cell lines and xenografts.
@en
Frequent inactivation of PTEN in prostate cancer cell lines and xenografts.
@nl
P2093
P1433
P1476
Frequent inactivation of PTEN in prostate cancer cell lines and xenografts.
@en
P2093
D C van Alewijk
G J van Steenbrugge
K G Hermans
R J Vlietstra
P304
P407
P577
1998-07-01T00:00:00Z